FDA Accepts Supplemental Application for XTANDI (Enzalutamide)
The FDA has accepted a supplemental application for XTANDI (enzalutamide) from Astellas.
Asset / Drug
Drug and asset intelligence for Astellas with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Androgen Receptor Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.